Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-l-histidyl-l-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), T4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment)
Muscle Recovery Moderate Evidence Evidence Rating: Moderate (Animal studies with consistent results) Muscle healing research shows promising results: Crush injury recovery Strain healing Post-surgical muscle repair Overcoming steroid-induced healing impairment While fewer studies exist compared to GI and tendon research, results are consistent and mechanisms are well-explained
The altered skin sensation has not been reported in the PIONEER-PLUS study or with injectable semaglutide 2.4 mg and its aetiology will need to be explored further in future studies
If you have any doubts, you can contact us anytime
[DOI] [PubMed] [Google Scholar] 81.Sharma N, Adjei AA
"DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status"
